QuidelOrtho Reports Q1 2026 Revenue Miss Amid Respiratory Slowdown and China Reimbursement Pressures
Event summary
- QuidelOrtho expects Q1 2026 revenue of $615-$620M, down from prior expectations due to weaker respiratory season and China reimbursement delays.
- U.S. Influenza-like Illness visits dropped ~30% YoY, contributing to revenue shortfall.
- China distributor sales slowed due to proposed NHSA reimbursement rate reductions.
- Middle East conflict delayed EMEA orders, further impacting Q1 revenue.
- Company maintains full-year 2026 guidance remains achievable despite near-term challenges.
The big picture
QuidelOrtho's Q1 2026 revenue miss highlights vulnerabilities in diagnostics companies reliant on seasonal respiratory products and international reimbursement structures. The broader industry faces similar pressures as healthcare systems prioritize cost containment, particularly in major markets like China. The company's ability to navigate these challenges will test its operational resilience and strategic flexibility in a volatile macroeconomic environment.
What we're watching
- Regulatory Headwinds
- Whether China NHSA reimbursement rate reductions will have prolonged impact on QuidelOrtho's Asia-Pacific revenue.
- Geopolitical Risks
- How continued Middle East conflict may affect EMEA supply chain and order delays.
- Operational Execution
- The pace at which QuidelOrtho can implement cost actions to offset Q1 revenue shortfall and meet full-year guidance.
Related topics